Advanced Malignant Pleural or Peritoneal Effusion in Patients Treated with Recombinant Adenovirus p53 Injection plus Cisplatin

Abstract

The aim of this study was to evaluate the efficacy of recombinant adenovirus p53 agent (rAd-p53) injection combined with cisplatin (CDDP) for the treatment of malignant pleural or peritoneal effusion. After puncture drainage, patients in the treatment group (n = 27) received intracavitary administration of rAd-p53 (2 × 10¹² virus particles) once a week for 4 weeks. At 48 h after each rAd-p53 injection, patients were given intracavitary administration of cisplatin 60 mg/m². This administration procedure continued once a week for 4 weeks. The control group (n = 21) received the same intracavitary therapy as the treatment group but without rAd-p53 therapy. Efficacy was evaluated by clinical observations, computed tomography, tumour markers, Karnofsky score and short-term follow-up. The total effective rates for the treatment group (63.0%) were significantly higher than for the control group (42.9%), suggesting that the treatment group benefited over the control group. In conclusion, rAd-p53 therapy is a safe and effective treatment for advanced malignant pleural or peritoneal effusion.

Keywords

Recombinant adenovirus p53 Cisplatin Gene therapy Malignant pleural effusion Malignant peritoneal effusion

References

Monti

Ciribilli

Jordan

: Transcriptional functionality of germ line p53 mutants influences cancer phenotype. Clin Cancer Res 2007; 13: 3789–3795.

Ostrowski

: An assessment of the long-term results of controlling the reaccumulation of malignant effusion using intracavity bleomycin. Cancer 1986; 57: 721–727.

Zhou

: Practice of Medical Oncology 2nd edn. Beijing: People's Medical Publishing House, vol 5, 2005; pp 47–48 [in Chinese].

Guo

Zen

Wang

: Therapeutic potential of recombinant adenovirus expressing p53 in hepatocellular carcinoma cell lines. Chin J Hepatol 2001; 9: 43–45 [in Chinese].

Swisher

Roth

: Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am 2002; 11: 521–535.

Guo

Wang

Chen

: Therapeutic potential of recombinant adenovirus expressing p53 on hepatocellular carcinoma cells possessing different p53 functional status. Chin J Gen Surg 2001; 16: 722–724 [in Chinese].

Quist

Wang-Grohrke

Köhler

: Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther 2004; 11: 547–554.

Peng

: Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016–1027.

Wang

Yan

: The expression of p53 in posttransfection cells with rAd-p53 gene and inhibition activity in vitro . Cancer Res Prevention Treatment 2007; 34: 185–188 [in Chinese].

10.

Swisher

Roth

Komaki

: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9: 93–101.

11.

Buller

Runnebaum

Karlan

: A phase L/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553–566.

12.

X-D

Yang

Z-B

Han

D-M

: The clinical effect of recombinant human Ad. p53 agent–Gendicine in advance cancer patients. Modern Oncol 2006; 14: 1295–1297 [in Chinese].

13.

Zhang

S-W

Xiao

S-W

Liu

C-Q

: Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: A phase II clinical trial of 42 cases. National Medical Journal of China 2003; 23: 2033–2035.

14.

Zhou

: Practice of Medical Oncology 2nd edn. Beijing: People's Medical Publishing House, vol 5, 2005; pp 92–95 [in Chinese].

15.

Yuan

Zhang

Miao XM

: Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms. Zhonghua Zhong Liu Za Zhi 2006; 28: 107–110 [in Chinese, English abstract].

16.

Jagelská

Brázda

Pecinka

: DNA topology influences p53 sequence-specific DNA binding through structural transitions within the target sites. Biochem J 2008; 412: 57–63.

17.

Di Ventura

Funaya

Antony

: Reconstitution of Mdm2-dependent post-translational modifications of p53 in yeast. PLoS ONE 2008; 3: e1507.

18.

Ohta

Tateishi

Kanai

: p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. Cancer Res 2005; 65: 10822–10829.

19.

Tian

Ding

Zhi

: Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 2006; 12: 415–419.

20.

Gai

Huang

: Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms. Ai Zheng 2006; 25: 954–959 [in Chinese, English abstract].

21.

Hostel

Hussain

Harris

: p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25: 177–181.

22.

Zumstein

Call

Merritt

: Safety of adenoviral vectors: Results of clinical investigations in 445 cancer patients treated with Advexin® (adenoviral p53) gene therapy. Mol Ther 2004; 9 (suppl 1): S385–S386.